| KAI Pharmaceuticals Announces Late Breaker Poster Presentation of KAI-4169 ... - MarketWatch (press release) |
|
|
MarketWatch (press release) Geoffrey A. Block, MD, Director of Clinical Research, Denver Nephrology, and a principal investigator in the Phase 2 study, stated, "KAI-4169 represents a new innovative therapeutic approach for the treatment of CKD-MBD. There is a consensus among |